「applicability」の検索結果

Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Builds and revises a complete skill DIRECTORY — SKILL.md, scripts, references, assets — and packages it. Use for "create a skill for X", "turn this into a skill", "update/improve this skill", "why doesn't my skill trigger", "review this SKILL.md", "package this skill", or when a repeated procedure should become a reusable artifact. Enforces the structure that makes skills work — a concrete procedure rather than a goal statement, an explicit applicability boundary, failure modes with their signals, a runtime verification step, and a description checked against the existing catalogue for confusability. For choosing whether the instruction should be a skill at all rather than project instructions or a prompt, use crafting-instructions. For writing quality inside the prose, use writing-instructions.

日本語の概要は準備中です。原文の説明を表示しています。

Use to assess regulatory applicability for products that may fall under AI regulation (EU AI Act, Article 50 transparency).

日本語の概要は準備中です。原文の説明を表示しています。

Research and populate tracked stablecoin compliance sidecars for the U.S. GENIUS Act, EU MiCA, or both. Use when adding or auditing authorization, applicability, pathway, or disclosure evidence.

日本語の概要は準備中です。原文の説明を表示しています。

Drafts a CCPA/CPRA-compliant privacy policy covering all required statutory disclosures under Cal. Civil Code §§ 1798.100–1798.199. Use when drafting or updating a California privacy policy, CCPA compliance notice, or consumer privacy disclosure for a business meeting CCPA applicability thresholds.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 platform features, including 77 prediction models with modeled-endpoint uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Knowledge base from DAFMAN 63-119 (15 April 2021), Mission-Oriented Test Readiness Certification. Use for continuous MOTRC replacing single-point OTRR thinking: framework/applicability, Certification Official vs PM roles, review cycle and exit criteria, certification memo/decertify gates, DT&E/contractor evidence, ITT integration and cyber resiliency, and the 31-template matrix. DAF T&E readiness process only—does not replace DoDI 5000.89, AFI 99-103, or multi-service lead policies.

日本語の概要は準備中です。原文の説明を表示しています。

Quietly reuse and improve verified coding lessons across agents. Use for a nontrivial debugging or implementation problem where an earlier solution could help, when a Blaze offer or receipt appears, or when the user asks to inspect, install, update, contribute to, or link Blaze. Check applicability, verify locally, and close the lookup with an honest outcome and contribution disposition without adding routine user-visible narration.

日本語の概要は準備中です。原文の説明を表示しています。

Execute production-readiness gates with applicability control, consolidate validation report, and issue final readiness verdict

日本語の概要は準備中です。原文の説明を表示しています。

Use when reviewing a project's architecture for design pattern applicability -- either validating a design document before implementation, or analyzing an existing codebase for pattern improvement opportunities.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Builds QSAR / QSPR models using chemprop D-MPNN, MolFormer, Uni-Mol, ChemBERTa, random forest baselines, and Gaussian processes with explicit handling of OECD 5 principles, applicability domain (kNN, leverage, conformal prediction, Mahalanobis), scaffold-balanced splits, ensemble uncertainty, calibration (Platt, isotonic), feature importance (SHAP, atomic attribution), and prospective validation. Use when building target-specific predictive models from in-house bioassay data, ADMET endpoints, or selectivity profiles.

日本語の概要は準備中です。原文の説明を表示しています。

Builds QSAR / QSPR models using chemprop D-MPNN, MolFormer, Uni-Mol, ChemBERTa, random forest baselines, and Gaussian processes with explicit handling of OECD 5 principles, applicability domain (kNN, leverage, conformal prediction, Mahalanobis), scaffold-balanced splits, ensemble uncertainty, calibration (Platt, isotonic), feature importance (SHAP, atomic attribution), and prospective validation. Use when building target-specific predictive models from in-house bioassay data, ADMET endpoints, or selectivity profiles.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Create, revise, or resolve applicability for SDD Composy user stories (US/SC) from an approved PRD and domain evidence, stopping at the human gate. Use after the PRD is approved — 'gerar as histórias de usuário', 'cenários de aceite', 'stories for prd-SLUG', 'is stories NOT_APPLICABLE here'. Do NOT use before the PRD is approved, for the TechSpec, or for user-story writing outside SDD.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 endpoints with uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES gold-standard endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Builds QSAR / QSPR models using chemprop D-MPNN, MolFormer, Uni-Mol, ChemBERTa, random forest baselines, and Gaussian processes with explicit handling of OECD 5 principles, applicability domain (kNN, leverage, conformal prediction, Mahalanobis), scaffold-balanced splits, ensemble uncertainty, calibration (Platt, isotonic), feature importance (SHAP, atomic attribution), and prospective validation. Use when building target-specific predictive models from in-house bioassay data, ADMET endpoints, or selectivity profiles.

日本語の概要は準備中です。原文の説明を表示しています。